Ренин - мишень прямой фармакологической блокады при артериальной гипертонии
- Авторы: Мухин Н.А.1, Фомин ВВ1, Mukhin NA2, Fomin VV2
-
Учреждения:
- Московская медицинская академия им. И. М. Сеченова
- Выпуск: Том 81, № 8 (2009)
- Страницы: 5-9
- Раздел: Передовая статья
- Статья получена: 09.04.2020
- Статья опубликована: 15.08.2009
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30455
- ID: 30455
Цитировать
Полный текст
Аннотация
Ключевые слова
Об авторах
Николай Алексеевич Мухин
Московская медицинская академия им. И. М. Сеченовад. м. н., проф., акад. РАМН, зав. кафедрой терапии и профболезней, директор клиники нефрологии, внутренних и профессиональных болезней им. Е. М. Тареева; Московская медицинская академия им. И. М. Сеченова
В В Фомин
Московская медицинская академия им. И. М. СеченоваМосковская медицинская академия им. И. М. Сеченова
N A Mukhin
V V Fomin
Список литературы
- Lindop G. B. M. Morphological aspects of renin synthesis, processing, storage and secretion. Kidney Int. 1987; 31(suppl. 20): 18-24.
- Takahashi S., Murakami K., Miyake Y. Activation of kidney prorenin by kidney kathepsin В isozymes. J. Biochem. 1982; 91: 419-422.
- Skott O. Renin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002; 282: R937-R939.
- Серов В. В., Пальцев М. А. Почки и артериальная гипертензия. М.: Медицина; 1993.
- Textor S. C., Wilcox C. S. Renal artery stenosis: a common, treatable cause of renal failure? Ann. Rev. Med. 2001; 52: 421-442.
- Федоров В. И., Перов Ю. Л. Резервная продукция ренина мезангиальными клетками клубочка при экспериментальном уменьшении почечного кровообращения. Бюл. экспер. биол. 1977; 83 (6): 656-659.
- Пальцев М. А., Кротовский Г. С., Егорова И. А., Щербюк А. Н. Состояние нейроэндокринных аппаратов почек при вазоренальной артериальной гипертензии как критерий прогнозирования результатов оперативного вмешательства. Арх. пат. 1982; 8: 62-71.
- Persson Р. В. Renin: origin, secretion and synthesis. J. Physiol. 2003; 552 (3): 667-671.
- Wagner C. Function of connexins in the renal circulation. Kidney Int. 2008; 3 (5): 547-555.
- Gomez R. A., Sequeira Lopez M. L Who and where is the renal baroreceptor: the connexin hypothesis. Kidney Int. 2009; 75 (5): 460-462.
- Chen M., Schnermann J., Smart A. M. et al. Cyclic AMP selectively increases renin mRNA stabilityin cultured juxtaglomerular granular cells. J. Biol. Chem. 1993; 268: 24138-24144.
- Krop M., Danser A. H. J. Circulating versus tissue angiotensin system: on the origin of (pro)renin. Curr. Hypertens. Rep. 2008; 10: 112-118.
- Nguyen G., Delarue F., Burcklé C. et al. Pivotal role of the rennin/pro-renin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002; 109: 1417-1427.
- Danser A. H. J., Deinum J. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005; 46: 1069-1076.
- Oliver J. A. Receptor mediated actions of renin and pro-renin. Kidney Int. 2006; 69: 13-15.
- Huang Y., Wongamorntham S., Kasting J. et al. Renin increases mesangial cell transforming growth factor-beta 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006; 69: 105-113.
- Nguen G., Danser A. H. J. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 2008; 93 (pt 5): 557-563.
- Ichihara A., Suzuki F., Nakagawa T. et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type la receptor-deficient mice. J. Am. Soc. Nephrol. 2006; 17: 1950-1961.
- Kaneshiro Y., Ichihara A., Sakoda M. et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)rennin receptor-transgenic rats. J. Am. Soc. Nephrol. 2007; 18: 1789-1795.
- Krebs C., Hamming I., Sadaghiani S. et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int. 2007; 72: 725-730.
- He M., Zhang L, Shao Y. et al. Inhibition of reninprorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur. J. Pharmacol. 2009; 606 (1-3): 155-161.
- Fisher N. D. L., Hollenberg N. K. Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. 2005; 16: 592-599.
- Staessen J. A., Li Y., Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449-1456.
- Johnson C. A., Wakerlin G. E. Antiserum for renin. Proc. Soc. Exp. Biol. (N 4). 1940; 44: 277-281.
- Haber E., Burton J. Inhibitors of the renin and their utility in physiologic studies. Fed. Proc. 1979; 38: 2768-2773.
- Boger J., Lohr N. S., Ulm E. H. et al. Novel renin inhibitors containing the amino acid statine. Nature, 1983; 303 (5912): 81-84.
- Himmelmann A., Bergbrant A., Svensson A. et al. Remikiren (Ro 42-5892)-an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am. J. Hypertens. 1996; 9: 517-522.
- Oh B.-H., Mitchell J., Herron J. R. et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol. 2007; 49: 1157-1163.
- Fisher N. D., Jan Danser A. H., Nussberger J. et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117 (25): 3199-3205.
- Dahlof В., Anderson D. R., Arora V. et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension (abstr). J. Clin. Hypertens. 2007; 9 (suppl. A): A157.
- Mooser V., Nussberger J., Juillerat L. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 1990; 15 (2): 276-282.
- Bleich M., Greger R. Mechanism of action of diuretics. Kidney Int. 1997; 51 (suppl. 59): S11-S15.
- Oparil S., Yarows S. A., Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomiased. Double-blind trial. Lancet 2007; 370: 221-229.
- Schmieder R. E., Philipp Т., Guerediaga J. et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren. a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-425.
- Чазова И. Е., Ратова Л. Г. Комбинированная терапия артериальной гипертонии. Сердце 2005; 4 (3): 120-126.
- Luetscher J. A., Kraemer F. B., Wilson D. M. et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular comlications. N. Engl. J. Med. 1985; 312: 1412-1417.
- Chiarelli F., Pomilio M., De Luca F. A. et al. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr. Nephrol. 2001; 16: 116-120.
- Kelly D. J., Zhang Y., Мое G. et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50 (11): 2398-2404.
- Parving H. H., Persson F., Lewis J. B. et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008; 358 (23): 2433-2446.
- Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 2009 [Epub Ahead of Print]; gfn721v1-gfn721.
Дополнительные файлы
![](/img/style/loading.gif)